Tag: COVID-19

World Mental Health Day

Posted on by pathwp

October 10th is World Mental Health Day and Atlantic PATH is pleased to be involved in multiple studies examining mental health and well-being. COVID Global Mental Health Consortium The COVID Global Mental Health Consortium was recently funded and includes 23 global cohorts representing 2.8 million participants. It will produce a global evaluation of pandemic-related mental health outcomes using individual-level harmonized longitudinal data. Research will begin this fall and we look forward to participating and contributing to this important work. Depression, Anxiety and Risk of Cancer Depression and anxiety have long been thought to be related to an increased cancer risk. The Psychosocial Factors and Cancer Incidence (PSY-CA) consortium is led from the Netherlands and includes Atlantic PATH, CARTaGENE (Quebec) and the Ontario Health Study. This study found that mental health was not related to an increased risk of cancer. Shift Work & Mental Health The relationship between mental health and shift work was evaluated among Atlantic PATH participants. Shift workers reported higher levels of each of the mental health domains compared to non-shift workers. Shift workers were more likely to have increased rates of depression and poor self-rated health, as well as depressive and anxiety symptom scores compared to non-shift workers. As a result, shift workers may be at increased risk of comorbidity, poor quality of life, missed work, and early retirement. Physical Activity and Self-Rated Health The population of Atlantic Canada is aging rapidly and has among the highest rates of chronic disease in the country. This study examined the association between physical activity and self-rated health among Atlantic PATH participants. The results suggest that physical activity is associated with and may help to improve perceived health status of individuals with one or more chronic conditions. The findings support literature suggesting that physical activity can be beneficial for adults as they age with chronic disease. Anxiety, Depression and Prostate Cancer Prostate cancer is the most prevalent form of cancer among males in Canada, and has one of the most favorable survival rates among all cancers. The incidence rates are expected to remain high with an aging population and an increase in asymptomatic detection. Prostate cancer survivors had higher odds of anxiety or depression symptoms compared to those with no history of cancer or a history of any other type of cancer. Prostate cancer survivors with a low household income had a higher rate of depression compared to those  with a history of another type of cancer and a high household income. Prostate cancer survivors who were treated with surgery had a higher odds of depression symptoms compared to those with a history of other types of cancer. Increased rates of anxiety and depression among males with a history of prostate cancer highlights the need for mental health screening among prostate cancer survivors. The findings highlight the importance of a multidisciplinary effort to prioritize and deliver comprehensive mental health support throughout the prostate cancer journey.  

CITF COVID-19 Immunity Task Force Databank

Posted on by pathwp

CanPath and its regional cohorts, including Atlantic PATH, are proud to be part of the COVID-19 Immunity Task Force (CITF) Databank with our COVID-19 serology study that includes participants across the country. The CITF Databank data holdings include data from 21 studies, including six multi-province studies “representing a wide range of population and community data from various regions of Canada. Access is free and open to researchers everywhere.” Details: https://www.covid19immunitytaskforce.ca/citf-databank/

COVID Global Mental Health Consortium Funded – 23 cohorts with 2.8 million participants

Posted on by pathwp

We’re excited to share that the collaborative project, “International Evaluation of Modifiable Social Determinants of Health on COVID-related Mental Health Outcomes” has been approved for funding from the National Institute of Mental Health (Mental Health Research Grant, award number 1RF1MH134638-01). Led by Dr. Jordan Smoller (Harvard University, Massachusetts General Hospital), Dr. Sarah Bauermeister (University of Oxford), and Dr. André Russowsky Brunoni (University of Sao Paulo), the COVID Global Mental Health Consortium (CGMHC) will produce a global evaluation of pandemic-related mental health outcomes using individual-level harmonized longitudinal data. The CGHMC is comprised of 23 global cohorts representing 2.8 million participants.1  This work will address critical knowledge gaps related to the impact of policy, psychological and social factors on mental health in the COVID-19 pandemic. 2 We look forward to participating in the CGHMC and contributing to this important research.   1 CGMHC cohorts include CanPath, Health and Retirement Study, Brains for Dementia Research, English Longitudinal Study of Ageing, National Study of Health and Development, Oxwell, Generation Scotland, UK Biobank, Igana Mayuge Health and Demographic Surveillance Site, Adolescent Brain Cognitive Development Study, All of Us, Einstein Study, Mass Gen Brigham Biobank, Study to Assess Risk and Resilience in Service Members Longitudinal Study, COVID-19 Mental Health Survey, FinnGen, Taiwan Biobank, University of College London COVID Study, The Irish Longitudinal Study on Ageing, COVIDMENT, Qatar Biobank, Brazilian High Risk Cohort Study, and the Brazilian Longitudinal Study of Adult Health (ELSA). 2 CanPath was represented on this application by Dr. Ellen Sweeney, Dr. Philip Awadalla, Dr. Robin Urquhart, and Mr. Yunsong Cui. Atlantic PATH is pleased to lead this work on behalf of CanPath.

Most CanPath study participants had infection-acquired antibodies but few suspected COVID-19

Posted on by pathwp

Dr. Victoria Kirsh presented at a CanPath webinar this week to present results from the SUPPORT-Canada study, funded by the federal COVID-19 Immunity Task Force (CITF). Data and blood spot samples were used from 22,300 participants from Atlantic PATH, CARTaGENE, the Ontario Health Study, Manitoba Tomorrow Project, Alberta’s Tomorrow Project, and BC Generations. Key findings include: 62% of participants had a COVID-19 infection based on anti-N measured antibody levels. Among those, 86% did not suspect they had ever had COVID-19. 95% of the COVID-19 infections were observed during the Omicron period. Risk of infection was increased among younger individuals, males, essential workers, and those who travelled. Participants with a reported COVID-19 infection reported symptoms from mild to severe, but few required hospitalization. The effectiveness of full or booster vaccination in preventing COVID-19 Omicron infection is short-term, only lasting 4 months. Time since last dose is a more important determinant of protection against infection than the number of doses. Antibody levels are correlates of vaccine-induced protection. Prior COVID-19 infection protects against reinfection for 8 months. The CanPath SUPPORT-Canada study has provided important findings related to the COVID-19 pandemic, vaccines and infections. With only 4 months of protection, these findings suggest that booster campaigns could be strategically used to rapidly boost immunity before upcoming waves of infection. Further, the longitudinal nature of CanPath participants ensures that we have a nationally representative population that can be followed for years to come (e.g., impact of Long COVID, future vaccinations, etc.). Link to recorded webinar: To come Link to webinar slide deck: https://www.covid19immunitytaskforce.ca/wp-content/uploads/2023/05/canpath-webinar-may-2023.pdf Link to CITF’s post: https://www.covid19immunitytaskforce.ca/most-canpath-study-participants-had-infection-acquired-antibodies-but-few-suspected-covid-19/

CanPath Webinar: COVID-19 Findings

Posted on by pathwp

CanPath Webinar: Real-World Insights on COVID-19 Vaccine Effectiveness and Infection Risk Factors from CanPath’s SUPPORT-Canada Study May 30th, 12-1pmEST/1-2pmAST Register: https://canpath.ca/2023/04/hybrid-event-covid-19-vaccine-effectiveness-support-canada-study/ Join us for an in-depth analysis of COVID-19 vaccine effectiveness based on real-world data from the SUrveying Prospective Population cOhorts for COVID-19 pRevalence and ouTcomes in Canada’ (SUPPORT-Canada) study. Led by Victoria Kirsh, this webinar will provide an overview of the study population, data collection, and statistical models used to analyze risk factors for infection and vaccine effectiveness against the Omicron variant. You’ll learn about the importance of time since last vaccination as the most critical determinant of protection against infection, more so than the number of vaccinations. Dr. Kirsh will also discuss the benefits and drawbacks of different vaccines and booster shots, including the latest findings on bivalent vs. monovalent boosters. Don’t miss this opportunity to stay up-to-date on the latest research and insights into COVID-19 vaccine effectiveness. About the Presenter: Dr. Victoria Kirsh is the Scientific Associate at the Ontario Health Study, one of CanPath’s regional cohorts. Dr. Kirsh completed a Ph.D. in Epidemiology from Yale University, an M.Sc. in Epidemiology from the University of Toronto and a B.Sc. in Microbiology and Immunology from McGill University. She completed a fellowship at the U.S. National Cancer Institute, Division of Cancer Epidemiology and Genetics. She worked as an Assistant Professor at the Dalla Lana School of Public Health, University of Toronto, and as a Scientist at Cancer Care Ontario before joining the Ontario Health Study.

The Ontario Public Health Convention (TOPHC)

Posted on by pathwp

Dr. Ellen Sweeney (Research Director, Atlantic PATH) and Dr. Victoria Kirsh (Scientific Associate, Ontario Health Study) were pleased to attend the Ontario Public Health Convention (TOPHC) on behalf of CanPath. Dr. Sweeney presented on CanPath’s resources for research on chronic disease and cancer and Dr. Kirsh presented on risk factors for COVID-19 infection among CanPath participants. TOPHC is created by and for public health professionals and delivers workshops, presentations, and keynote presentations focused on the unique experiences, challenges and opportunities in public health today. TOPHC events offer a chance for public health professionals to learn from each other, get inspired, provoke thought and move forward to make a difference in their careers and communities (https://www.tophc.ca/).

Congratulations to Dr. Robin Urquhart and the CanPath team across the country!

Posted on by pathwp

Funded by the Canadian Cancer Society Data Transformation Grant, this work will connect cancer registry and administrative health data with CanPath data creating a unified resource for cancer research in Canada. https://bit.ly/3OojlZ2 Urquhart R, Awadalla P, Bhatti P, Dummer T, Gravel S, Vena J, Alvi R, Broet P, Kendell C, Kirsh V, Lettre G, Skead K, Sweeney E, Turner D. Harnessing the power of linked data to understand cancer and its outcomes: a national linkage project. March 2022-March 2023, CCS Data Transformation Grant. Canada has a wealth of health care and health research data, but numerous barriers prevent efficient sharing of these datasets between provinces. This, combined with further difficulties with linking datasets together, causes major limitations in using the data productively to improve the health of Canadians. With support from the Canadian Cancer Society, Dr Urquhart will lead a team to connect several cancer registry and administrative health data repositories, creating a unified resource for cancer research in Canada. One of the datasets, CanPath, contains data on 1 in 100 Canadians, including lifestyle, family histories, genetics and environment and this, combined with other datasets, will be analysed to understand the causes of cancer and what happens to people with cancer in the short- and long-term. The researchers will also be able to ask important questions about the impact of the COVID-19 pandemic on people who have been diagnosed with cancer during this time. Linking these huge datasets will provide a very important resource for cancer research in Canada.

CanPath to Study the Impact and Immune Response to COVID-19 Infection and Vaccination

Posted on by pathwp

The Government of Canada is investing $1.9m through the COVID-19 Immunity Task Force (CITF) to fund an extension of CanPath’s COVID-19 Antibody Study over a longer period of time, allowing for additional collection of blood samples and questionnaires. The CanPath COVID-19 Antibody Study is implemented in collaboration with CanPath’s regional cohorts, including Atlantic PATH, CARTaGENE (Quebec), the Ontario Health Study, the Manitoba Tomorrow Project, Alberta’s Tomorrow Project, and the BC Generations Project. CanPath is a national population health research platform that follows the health of 330,000 volunteer Canadians (or approximately 1% of the population). Its pan-Canadian COVID-19 Antibody Study will now collect a second dried blood spot sample from over 20,000 Canadians, aged 30 and older. Researchers will test the samples for presence and level of antibodies to SARS-CoV-2, produced in response to either vaccination or past infection with the novel coronavirus. Please click here for additional details: https://bit.ly/3I6lWE5